Flare Therapeutics Presents Data at AACR 2024 Annual Meeting Characterizing PPARG-Derived Immune Cell Patterns in Urothelial Cancer Patients After Anti-PD1 Therapy

Posted on by

— Data support the potential to explore lead Phase 1 monotherapy asset FX-909 in combination with an anti-PD1 agent — CAMBRIDGE, Mass., April 9, 2024 /PRNewswire/ — Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.